



July 23, 2026

Nevada Medicaid Web Announcement 3971

Attention Nevada Medicaid-enrolled 340B Covered Entities:

Nevada Medicaid Fee-For-Service (FFS) Will Integrate the 340B Ceiling Price into the 340B Reimbursement Methodology Beginning October 1, 2026

Starting October 1, 2026, reimbursement for qualifying 340B outpatient drug claims under the Fee-for-Service program may reflect the 340B ceiling price when it is the lowest applicable value within the established drug reimbursement logic.

The 340B ceiling price is determined by the Average Manufacturer Prices (AMP) and Unit Rebate Amounts (URA). Covered entities are required to submit their 340B AAC to Nevada Medicaid. For additional information about calculating ceiling prices, please visit HRSA's website on [340B Ceiling Price Calculation](#).

Prime Therapeutics cannot disclose individual 340B unit pricing. Pricing disputes related to the HRSA 340B ceiling price must follow the HRSA-directed 340B Administrative Dispute Resolution process, which is available at the HRSA website under [340B Administrative Dispute Resolution](#).

For additional guidance on 340B billing, please refer to the [Nevada Medicaid and Nevada Check Up Pharmacy Manual](#). Policy and billing questions may be directed to RxInfo@nvha.nv.gov.